Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Scinai Immunotherapeutics Ltd. - American Depositary Shares (NQ:SCNI)

0.2527 +0.0071 (+2.89%)
Streaming Delayed Price Updated: 1:08 PM EDT, Jul 22, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Scinai Immunotherapeutics Ltd. - American Depositary Shares

< Previous 1 2 3 4 5 6 Next >
BioMedNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Showcasing Services, Meeting with Investors at Upcoming BIO-Europe Spring 2024
Via Investor Brand Network
Siteman Cancer Center Starts Offering Novel Cell-Based Immunotherapy Against Melanoma
Via Investor Brand Network
BioMedNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Appoints Liat Halpert as Head of Business Development, Sales
Via Investor Brand Network
The Right to Health During Humanitarian Crises Should Include Noncommunicable Diseases
Via Investor Brand Network
Potential Complications of Untreated Psoriasis
Via Investor Brand Network
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's After-Market Session ↗
 
Via Benzinga
Scientists Uncover Vital T-Cells in Kids’ Brains That Could Fight Brain Cancers
Via Investor Brand Network
BioMedNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Scientific Research Collaborator Receives Prestigious Louis-Jeantet Prize
Via Investor Brand Network
BioMedNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) CEO Releases Shareholder Letter
Via Investor Brand Network
Shining Spotlight on How Vitiligo Could Be Connected to Other Autoimmune Disorders
Via Investor Brand Network
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
 
Via Benzinga
BioMedNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Enters Agreement for Million-Dollar Exercise of Outstanding Warrants
Via Investor Brand Network
BioMedNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Announces January Analyst, Investor Webinar
Via Investor Brand Network
New Research Redefines Pathophysiology of Rheumatoid Arthritis, Paves Way for Precision Treatments
Via Investor Brand Network
BioMedNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Reports on Preclinical Results from Psoriatic Human Skin Trial
Via Investor Brand Network
BioMedNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Announced Peer-Reviewed Journal Publishes Data Supporting NanoAbs
Via Investor Brand Network
Many Fellowship Programs for Infectious Disease Specialists Remain Unfilled in US
Via Investor Brand Network
BioMedNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Announces Maturity Extension of EIB Finance Facility
Via Investor Brand Network
Autoimmunity Patients Face Cost, Diagnosis, Care Challenges
Via Investor Brand Network
New, Deadly Infectious Diseases Could Emerge as Climate Change Worsens
Via Investor Brand Network
Topics Climate Change
BioMedNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Receive $900K IIA Grant for New CDMO Business Unit
Via Investor Brand Network
Topics Economy
BioMedNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Releases Status Report on NASDAQ Compliance
Via Investor Brand Network
News headline image
Scinai Immunotherapeutics Announces Award of Non-Dilutive Grant from Israel Innovation Authority Supporting its New CDMO Business Unit
From Scinai Immunotherapeutics Ltd.
Via GlobeNewswire
News headline image
Scinai Immunotherapeutics Provides Update Regarding Nasdaq Compliance
From Scinai Immunotherapeutics Ltd.
Via GlobeNewswire
BioMedNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Releases Q3 2023 Financial Report, Reports Possible Adjustment of Facility Terms by EIB
Via Investor Brand Network
News headline image
European Investment Bank (EIB) considering extending maturity of its financial facility contract with Scinai Immunotherapeutics in light of Scinai’s recent strategic pivot
From Scinai Immunotherapeutics Ltd.
Via GlobeNewswire
News headline image
Scinai Reports Third Quarter 2023 Financial Results and Provides Business Update
From Scinai Immunotherapeutics Ltd.
Via GlobeNewswire
Study Identifies Immune Cells Responsible for Severe Asthma
Via Investor Brand Network
BioMedNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Announces Participation at BIO-Europe Munich 2023
Via Investor Brand Network
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.